Another dual AXL/MERTK inhibitor INCB081776 is also being tested in a phase I study as monotherapy and in combination with retifanlimab (anti-PD-1 antibody) in patients with relapsed/refractory AML or certain advanced-stage solid tumors (NCT03522142). The gene discussed is MERTK; the disease is acute myeloid leukemia.